Endoprothèses au sirolimus : données des études RAVEL et SIRIUSBLANCHARD, D; BENSOUDA, C; DANCHIN, N et al.Annales de cardiologie et d'angéiologie (Paris). 2004, Vol 53, pp 9-12, issn 0003-3928, 4 p., SUP1Article

Rapamycin : Clinical results and future opportunitiesKAHAN, Barry D; CAMARDO, Joseph S.Transplantation. 2001, Vol 72, Num 7, pp 1181-1193, issn 0041-1337Article

Direct stenting limits sirolimus-eluting stent edge neointimal thickeningGUERIN, Patrice; GOUËFFIC, Yann; HEYMANN, Marie-Francoise et al.Journal of vascular surgery. 2007, Vol 46, Num 2, pp 354-359, issn 0741-5214, 6 p.Article

Rapamycin pre-treatment protects against apoptosisRAVIKUMAR, Brinda; BERGER, Zdenek; VACHER, Coralie et al.Human molecular genetics (Print). 2006, Vol 15, Num 7, pp 1209-1216, issn 0964-6906, 8 p.Article

A selective small molecule c-MET inhibitor, PHA665752, cooperates with rapamycinMA, Patrick C; SCHAEFER, Erik; CHRISTENSEN, James G et al.Clinical cancer research. 2005, Vol 11, Num 6, pp 2312-2319, issn 1078-0432, 8 p.Article

Immunosuppressive drug rapamycin restores sporulation competence in industrial yeastsNAKAZAWA, Nobushige; NIIJIMA, Seiko; TANAKA, Yukari et al.Journal of bioscience and bioengineering. 2012, Vol 113, Num 4, pp 491-495, issn 1389-1723, 5 p.Article

Stent coronaire à libération de sirolimus : les leçons de l'expérience de RotterdamLEMOS, P. A; MCFADDEN, E. P; ONG, A. T. L et al.Annales de cardiologie et d'angéiologie (Paris). 2004, Vol 53, pp 32-35, issn 0003-3928, 4 p., SUP1Article

Functional interaction of mammalian target of rapamycin complexes in regulating mammalian cell size and cell cycleROSNER, Margit; FUCHS, Christiane; SIEGEL, Nicol et al.Human molecular genetics (Print). 2009, Vol 18, Num 17, pp 3298-3310, issn 0964-6906, 13 p.Article

Coronary uptake of gallium-67 citrate after implantation of sirolimus-eluting stentKRITHARIDES, Leonard; YIANNIKAS, John; BRIEGER, David et al.Circulation (New York, N.Y.). 2004, Vol 109, Num 17, issn 0009-7322, p. 2156Article

Pharmacokinetics and metabolism of sirolimusGALLANT-HAIDNER, H. L; TREPANIER, D. J; FREITAG, D. G et al.Therapeutic drug monitoring. 2000, Vol 22, Num 1, pp 31-35, issn 0163-4356Article

Sirolimus-associated diffuse alveolar hemorrhageVLAHAKIS, Nicholas E; RICKMAN, Otis B; MORGENTHALER, Timothy et al.Mayo Clinic proceedings. 2004, Vol 79, Num 4, pp 541-545, issn 0025-6196, 5 p.Article

Activation of mammalian target of rapamycin in cytomegalic neurons of human cortical dysplasiaLJUNGBERG, M. Cecilia; BHATTACHARJEE, Meenakshi B; YAOJUAN LU et al.Annals of neurology. 2006, Vol 60, Num 4, pp 420-429, issn 0364-5134, 10 p.Article

Du sirolimus au stent Cypher® : les étapes d'une victoire contre la resténoseFONTES, I; BARROW, D.Annales de cardiologie et d'angéiologie (Paris). 2004, Vol 53, pp 3-8, issn 0003-3928, 6 p., SUP1Article

Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferationMATEO-LOZANO, Silvia; TIRADO, Oscar M; NOTARIO, Vicente et al.Oncogene (Basingstoke). 2003, Vol 22, Num 58, pp 9282-9287, issn 0950-9232, 6 p.Article

Les inhibiteurs de la mTOR et le FTY 720 = Inhibitors of mammalian target of rapamycin (mTOR)SOLIGNAC, Marie; MOREL, D.La Presse médicale (1983). 2001, Vol 30, Num 24, pp 35-37, issn 0755-4982, 2Conference Paper

INHIBITION OF RAPAMYCIN-INDUCED AUTOPHAGY CAUSES NECROTIC CELL DEATH ASSOCIATED WITH BAX/BAD MITOCHONDRIAL TRANSLOCATIONCARLONI, S; BUONOCORE, G; LONGINI, M et al.Neuroscience. 2012, Vol 203, pp 160-169, issn 0306-4522, 10 p.Article

Switching to Sirolimus Monotherapy for De Novo Tumors After Liver Transplantation. A Preliminary ExperienceJIMENEZ-ROMERO, Carlos; MANRIQUE, Alejandro; COLINA, Francisco et al.Hepato-gastroenterology. 2011, Vol 58, Num 105, pp 115-121, issn 0172-6390, 7 p.Article

Four-Year Clinical Follow-Up of the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital RegistryDAEMEN, Joost; KUKREJA, Neville; VAN TWISK, Piet-Hein et al.The American journal of cardiology. 2008, Vol 101, Num 8, pp 1105-1111, issn 0002-9149, 7 p.Article

PEComas : the past, the present and the futureMARTIGNONI, Guido; PEA, Maurizio; REGHELLIN, Daniela et al.Virchows Archiv. 2008, Vol 452, Num 2, pp 119-132, issn 0945-6317, 14 p.Article

Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor : compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTORVEVERKA, V; CRABBE, T; BIRD, I et al.Oncogene (Basingstoke). 2008, Vol 27, Num 5, pp 585-595, issn 0950-9232, 11 p.Article

Proteomic analysis of anti-angiogenic effects by a combined treatment with vinblastine and rapamycin in an endothelial cell lineCAMPOSTRINI, Natascia; MARIMPIETRI, Danilo; TOTOLO, Andrea et al.Proteomics (Weinheim. Print). 2006, Vol 6, Num 15, pp 4420-4431, issn 1615-9853, 12 p.Article

Production of novel rapamycin analogs by precursor-directed biosynthesisRITACCO, Frank V; GRAZIANI, Edmund I; SUMMERS, Mia Y et al.Applied and environmental microbiology (Print). 2005, Vol 71, Num 4, pp 1971-1976, issn 0099-2240, 6 p.Article

Metabolic interaction between cyclosporine and sirolimusSHUANG BAI; STEPKOWSKI, Stanislaw M; KAHAN, Barry D et al.Transplantation. 2004, Vol 77, Num 10, pp 1507-1512, issn 0041-1337, 6 p.Article

Rapamycin-eluting stents for the treatment of unprotected left main coronary diseaseSUAREZ DE LEZO, Jose; MEDINA, Alfonso; URENA, Isabel et al.The American heart journal. 2004, Vol 148, Num 3, pp 481-485, issn 0002-8703, 5 p.Article

Treatment of very small vessels with 2.25-mm diameter sirolimus-eluting stents (from the RESEARCH registry)LEMOS, Pedro A; ARAMPATZIS, Chourmouzios A; SIANOS, Georgios et al.The American journal of cardiology. 2004, Vol 93, Num 5, pp 633-636, issn 0002-9149, 4 p.Article